^
Association details:
| Biomarker: | FANCI mutation + FLT1 mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | buparlisib (AN2025) (PI3K inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase I study of the PI3K inhibitor buplarlisib (B) with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck (LASCCHN).
Excerpt:
In this phase I study, the oral pan-PI3K inhibitor B combined with CRT was tested in pts with stage III/IV LASCCHN...4/5 cases with response to B alone had sequencing results and demonstrated mutations in FANCD2/EP300; FANCA/FGFR3; FANCI/FLT1 and PIC3CA/EP300.
Secondary therapy:
cisplatin
DOI:
10.1200/JCO.2018.36.15_suppl.6071
Trial ID:
